{"id":"NCT01529515","sponsor":"Janssen Research & Development, LLC","briefTitle":"A Study of Paliperidone Palmitate 3 Month Formulation for the Treatment of Patients With Schizophrenia","officialTitle":"A Randomized, Multicenter, Double-Blind, Relapse Prevention Study of Paliperidone Palmitate 3 Month Formulation for the Treatment of Subjects With Schizophrenia","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-05","primaryCompletion":"2014-04","completion":"2014-04","firstPosted":"2012-02-09","resultsPosted":"2015-06-18","lastUpdate":"2016-05-11"},"enrollment":509,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Schizophrenia"],"interventions":[{"type":"DRUG","name":"PP3M 175 mg eq.","otherNames":[]},{"type":"DRUG","name":"PP3M 263 mg eq.","otherNames":[]},{"type":"DRUG","name":"PP3M 350 mg eq.","otherNames":[]},{"type":"DRUG","name":"PP3M 525 mg eq.","otherNames":[]},{"type":"DRUG","name":"Placebo (20% Intralipid emulsion)","otherNames":[]}],"arms":[{"label":"Paliperidone palmitate 3-month (PP3M)","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to evaluate the efficacy of paliperidone palmitate 3 month formulation (PP3M) compared with placebo in delay of the time to first occurrence of relapse of the symptoms of schizophrenia.","primaryOutcome":{"measure":"Time to Relapse During the Double-Blind Phase","timeFrame":"Approximately Week 60","effectByArm":[{"arm":"Double-Blind Phase: Placebo","deltaMin":395,"sd":null},{"arm":"Double-Blind Phase: Paliperidone Palmitate 3-Month (PP3M)","deltaMin":null,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":7},"locations":{"siteCount":53,"countries":["United States","Colombia","Malaysia","Mexico","Romania","South Korea","Turkey (TÃ¼rkiye)","Ukraine"]},"refs":{"pmids":["32606705","30994855","28640988","27743205","26306819","25820612"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":33,"n":506},"commonTop":["Insomnia","Anxiety","Weight Increased","Headache","Injection Site Pain"]}}